Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 and the Dow Jones Industrial Average DJIA rising 0.

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 ( ^GSPC 1.00%) and 28.6% for the Nasdaq Composite.

Palantir stock rebounds, sales of Eli Lilly’s blockbuster GLP-1 medicines miss estimates, and Boeing’s 2024 deliveries fall sharply from a year earlier.

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check. The S&P 500 edged up 0.1% Tuesday, and three out of four stocks in the index were higher.

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is rising following an encouraging update on inflation.

though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as three out of every four stocks in the index climbed. The Dow Jones Industrial Average added ...

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and the Nasdaq,

Eli Lilly ( LLY 2.45%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival. That performance was in contrast to the S&P 500 's ( ^GSPC -0.29%) trajectory; the closely watched index sank marginally by 0.3%.

Major stock indexes weren't moving much in the stock market today, but there were plenty of big gainers below the surface.

Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep correction. Lilly is by no means in bad shape, but because the stock's price has become so inflated in recent years, so have expectations.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow